According to Health Minister Mikhail Murashko, the number of clinical trials for drugs supported by the Ministry of Health of the Russian Federation has increased by over 3.5 times in the past three years. “The ongoing transformations in the management of applied medical and scientific research are already yielding results today. <…> Registered medicinal products are a clear confirmation of this: 8 medicinal products and 16 new medical products are what is already a result,” the minister clarified.
In April 2024, the Russian Ministry of Health registered Biocad’s groundbreaking drug for the treatment of ankylosing spondylitis. This pioneering medication signifies a potential breakthrough, as it aims not only to alleviate the symptoms of the disease but also to halt its progression, marking a significant advance in the field of medical treatment.
“The developed drug allows us to destroy pathological T-lymphocytes that attack the body’s own cells. Initial clinical studies have confirmed that the development of the disease stops (without reducing the activity of the body’s immune system as a whole),” the Ministry of Health explained earlier.
According to Murashko, the appearance of such a drug in Russia could become a reason for medical tourism from other countries.
